Skip to main content
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
1.050
-0.040 (-3.67%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Virax Biolabs Group Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Sep '24 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20
Revenue
0.080.160.01-0.120.1
Revenue Growth (YoY)
7.03%1727.11%--23.97%-
Cost of Revenue
0.050.110.01-0.130.05
Gross Profit
0.030.05-0--0.010.05
Selling, General & Admin
4.634.593.551.30.510.61
Research & Development
1.681.562.180.430.120.09
Operating Expenses
6.316.165.731.730.640.7
Operating Income
-6.28-6.11-5.73-1.73-0.64-0.65
Interest Expense
-0.04-0.03-0.02-0.02-0.03-0.09
Other Non Operating Income (Expenses)
-0.01-0.02-0-000
EBT Excluding Unusual Items
-6.33-6.15-5.75-1.75-0.67-0.74
Asset Writedown
-0.39-0.39----
Legal Settlements
-0.21-0.21----
Other Unusual Items
0.210.010.29---
Pretax Income
-6.72-6.74-5.46-1.75-0.67-0.74
Earnings From Continuing Operations
-6.58-6.74-5.46-1.75-0.67-0.74
Minority Interest in Earnings
00.0100.040.020.03
Net Income
-6.58-6.73-5.46-1.71-0.65-0.71
Net Income to Common
-6.58-6.73-5.46-1.71-0.65-0.71
Shares Outstanding (Basic)
321100
Shares Outstanding (Diluted)
321100
Shares Change (YoY)
50.43%88.75%11.15%297.67%130.43%-
EPS (Basic)
-2.46-3.36-5.13-1.79-2.71-6.81
EPS (Diluted)
-2.47-3.36-5.13-1.79-2.71-6.81
Free Cash Flow
-5.28-7.2-4.18-0.81-0.59-0.74
Free Cash Flow Per Share
-1.98-3.59-3.93-0.85-2.45-7.13
Gross Margin
39.59%32.34%-15.94%--7.62%45.81%
Operating Margin
-7397.95%-3903.69%-66963.68%--520.54%-652.05%
Profit Margin
-7753.22%-4304.81%-63748.32%--525.75%-711.32%
Free Cash Flow Margin
-6220.66%-4602.71%-48823.35%--476.65%-745.54%
EBITDA
-6.12-6.05----
D&A For EBITDA
0.160.05----
EBIT
-6.28-6.11-5.73-1.73-0.64-0.65
Revenue as Reported
----0.120.1
Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q